X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2022 16:05 ET
|
X4 Pharmaceuticals
BOSTON, Nov. 04, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of...
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 03, 2022 06:05 ET
|
X4 Pharmaceuticals
Following positive mavorixafor Phase 1b data release in multiple chronic neutropenic disorders, X4 continues to look forward to top-line results from its pivotal Phase 3 trial in WHIM syndrome in the...
X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer
October 26, 2022 08:00 ET
|
X4 Pharmaceuticals
A seasoned leader in the launch of rare and specialty pharmaceuticals, Mr. Baldry is expected to join X4 on November 3, 2022 BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc....
X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022
October 20, 2022 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Oct. 20, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of...
X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)
September 27, 2022 07:50 ET
|
X4 Pharmaceuticals
100% of study participants (n=25) achieved robust responses to oral mavorixafor 100% of neutropenic participants (n=14) achieved normalized neutrophil counts Robust responses achieved across...
X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia
August 31, 2022 08:30 ET
|
X4 Pharmaceuticals
BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small-molecule therapeutics to benefit people...
X4 Pharmaceuticals to Present at Canaccord Genuity’s 42nd Annual Growth Conference
August 08, 2022 16:05 ET
|
X4 Pharmaceuticals
BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 04, 2022 07:05 ET
|
X4 Pharmaceuticals
Highlights notable upcoming milestones including data from Phase 1b trial in chronic neutropenia, expected in late September, and results from global, pivotal Phase 3 trial in WHIM syndrome, expected...
X4 Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022
July 26, 2022 16:05 ET
|
X4 Pharmaceuticals
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
X4 Pharmaceuticals Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones
July 20, 2022 16:10 ET
|
X4 Pharmaceuticals
Company now focused on advancing lead clinical candidate mavorixafor in chronic neutropenic disorders, including WHIM syndrome Important mavorixafor clinical milestones anticipated in 2H 2022,...